Open-to-Accrual Therapeutic Trials


Malignant Hematology

Protocol ID

Official Title

PI Name

Lead CRC

Disease Site

Phase

I137-102        ClinicalTrials.gov:   NCT02931110

A Phase 1 Dose-Escalation and Cohort-Expansion Study of Intravenous CBL0137 in Subjects With Previously Treated Hematological Cancers C. Sportes Sandra Wall Heme Malignancies I

IMDZ-G142      ClinicalTrials.gov: NCT02501473

 

Phase 1/2 Study of Intratumoral G100 Therapy in Patients With or Without Pembrolizumab in Patients Wuth Follicular Non-Hodgkin's Lymphoma L. Bryan Sandra Wall Non-Hodgkin's Lymphoma I/II

INCB-39110-206 ClinicalTrials.gov:  NCT02760485

An Open Label Phase 1/2 Study of INCB039110 in Combination with Ibrutinib in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma L. Bryan Sandra Wall Large B-Cell Lymphoma I/II

NLG-2106        ClinicalTrials.gov: NCT02835729

A Phase 1b/Randomized Phase 2a Trial of Indoximod in Combination with Idarubicin and Cytarabine in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) J. Pantin Sandra Wall Acute Myeloid Leukemia Ia/IIb

VT3996-201  ClinicalTrials.gov:  NCT03397706

A Phase 1b/2 Open-Label, Dose Escalation and Expansion Study of Orally Administered VRx3996 and Valganciclovir in Subjects with Epstein-Barr Virus-Associated Lymphoid Malignancies Protocol Type: Treatment L. Bryan Sandra Wall Epstein-Barr Virus Associated Lymphoid Malignancies Ib/II

ICT-8    ClinicalTrials.gov:  NCT02802267

Efficacy Study of Inecalcitol in Combination With Decitabine in Acute Myeloid Leukemia Patients Unfit for Standard Chemotherapy J. Pantin Sandra Wall Acute Myeloid Leukemia II

MEI-011 ClinicalTrials.gov:  NCT03151304

A Two-Stage, Open-Label Followed by Placebo-Controlled Phase 2 Study of Pracinostat and Azacitidine in Patients with IPSS-R High and Very High Risk Myelodysplastic Syndromes Previously Untreated with Hypomethylating Agents Protocol Type: Treatment J. Pantin Sandra Wall Myelodysplastic Syndromes II

NU-16H07 ClinicalTrials.gov:  NCT03077828 

(NU-16H07) Phase II Trial of Pembrolizumab in Combination with ICE Salvage Chemotherapy for Relapsed/Refractory Hodgkin Lymphoma L. Bryan Sandra Wall Hodgkin Lymphoma II

S1318  ClinicalTrials.gov: NCT02143414

A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients Greater than or Equal to 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (PH Negative) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517), Prednisone and Blinatumomab for Patients Greater Than or Equal to 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (PH Positive) ALL S. Ghamande Inquiries Acute Lymphoblastic Leukemia II

2215-CL-0201 ClinicalTrials.gov: NCT02752035

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy J. Pantin Sandra Wall Acute Myeloid Leukemia II/III

A051301 ClinicalTrials.gov: NCT02443077

A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of the Activated B-cell Subtype S. Ghamande Inquiries Large B-Cell Lymphoma III

BGB-3111-304 ClinicalTrials.gov:  NCT03336333

An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma L. Bryan Crystal Durden Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma III

EA4151 ClinicalTrials.gov: NCT03267433

A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission S. Ghamande Sandra Wall  Mantle Cell Lymphoma III